The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

In a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...

Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Merck MRK announced FDA approval for its prophylactic long-acting monoclonal antibody, clesrovimab, for the prevention of RSV ...

The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

MSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...